Pfizer To Use India Location To Concentrate On Indian Ailments
This article was originally published in PharmAsia News
Executive Summary
When Pfizer stepped up its presence in the Indian pharmaceutical market, it did so to concentrate on drugs specific to Indian ailments. With the move to India, Pfizer plans to focus on cancer, diabetes, inflammation, neurological disorders and other ailments at the regional level. Among the plans are trials of Sutent (sunitinib malate) for combating kidney cancer. Pfizer's India presence also is aimed at diabetes, inflammation and neurological disorders as well as breast, cervical and lung cancers. (Click here for more